Alvotech (ALVOW)

“Biosimilars are not generics—they are complex biological molecules manufactured in living cells, and getting them right requires the scale, regulatory expertise, and capital that few companies outside the traditional pharma giants possess.”

Alvotech warrants (ALVOW) represent leveraged calls on the common stock of Alvotech, a company formed through a SPAC merger to develop and commercialise biosimilar drugs and other biopharmaceutical products. The warrants embody a bet on whether Alvotech can execute in a sector that is highly regulated, capital intensive, and dominated by established pharmaceutical giants. To understand the warrant’s value, one must first understand what Alvotech is and why the biosimilar market matters.

What Alvotech is and what biosimilars mean

Alvotech is a biopharmaceutical company that focuses on developing biosimilars—drugs that are designed to be biologically equivalent to existing approved biologic medicines. A biologic drug is manufactured using living cells or organisms (such as bacteria or mammalian cells) and is far more complex than a traditional chemical drug. Biologics include monoclonal antibodies used in cancer and autoimmune disease, insulin and growth hormones used in endocrinology, and blood-derived treatments. Once a biologic drug loses its patent protection, manufacturers can create a biosimilar—a new drug that copies the original’s structure and function closely enough to be considered therapeutically equivalent, yet is separately manufactured and separately approved.

Biosimilars are not generics. A generic drug is a straightforward chemical reproduction of an approved medicine; making generics is usually cheap, and generic margins are thin. A biosimilar is far more complex to develop and manufacture because it must be created in living cells and must demonstrate that it is sufficiently similar to the original drug that a patient switching from the original to the biosimilar would see no meaningful difference. Regulatory approval for a biosimilar takes years and costs hundreds of millions of dollars. The payoff, if successful, is the ability to sell a version of a blockbuster biologic drug at a lower price than the originator, capturing market share.

The opportunity and the market structure

The biosimilar market exists because major biologic drugs are coming off patent. When a drug loses its patent, competitors can step in. In the United States and Europe, regulatory pathways (the 351(k) pathway in the U.S. and similar frameworks in Europe and Japan) now allow manufacturers to file for biosimilar approval, demonstrating equivalence rather than redoing the original drug’s full development program. This creates a genuine business opportunity: a manufacturer who can develop a biosimilar for a blockbuster biologic drug that is losing patent protection can sell it at a significant discount to the original—say, 20 to 30 percent below the originator’s price—and still be highly profitable.

Alvotech’s strategy has been to identify biologic drugs coming off patent protection and develop biosimilar candidates for them. The company has worked on products in diabetes, oncology, autoimmune disease, and other therapeutic areas. The hope is that once Alvotech commercialises these biosimilars, they will generate steady revenue streams.

Geography and the global biotech footprint

Alvotech operates as a development-stage company with operations spanning multiple continents. The company has had development teams and facilities in Iceland, the United States, Europe, and other regions, reflecting the reality that biopharmaceutical development is globally distributed. Manufacturing biosimilar drugs requires specialised facilities, often located in countries with strong regulatory environments and access to contract manufacturing organisations. Alvotech’s strategy has involved partnerships with manufacturing and distribution partners rather than building all manufacturing capacity in-house—an asset-light approach common in biotech.

The company’s ability to navigate regulatory and commercial environments across geographies is crucial. Biosimilar companies must secure approvals from the FDA, the European Medicines Agency, and other national regulators before commercialising. They must also negotiate pricing and reimbursement with healthcare systems and payers in each region. A company with weak relationships or regulatory experience in key markets will struggle.

The capital intensity and cash burn reality

Biopharmaceutical development is extremely capital intensive. Clinical trials, manufacturing process development, regulatory consultants, and facility costs mount rapidly. A company developing one or more biosimilar candidates will burn through substantial cash before any product achieves regulatory approval and market launch. Only after successful approval and commercialisation can a biotech company begin to recover its investment.

Alvotech has required significant capital to pursue its biosimilar pipeline. A SPAC merger provided that capital, but whether it is sufficient to bring multiple candidates to market and achieve profitability is an open question. Biotech companies often require additional funding rounds or partnerships to sustain operations through multiple clinical and regulatory milestones.

Competition and the timing challenge

The biosimilar market is increasingly crowded. Established pharmaceutical companies (Amgen, Sandoz, Pfizer, others) have launched biosimilars and have strong commercial infrastructure to market them. Smaller biotech companies entering the space must differentiate on cost of development, speed to market, or selection of high-value target drugs. Alvotech competes by choosing targets and executing development programmes faster and more cheaply than rivals, but this is not always feasible. Additionally, biosimilar pricing is under constant pressure as payers and healthcare systems push for lower and lower discounts to originator biologics. If prices fall faster than Alvotech expected, the economics of its candidates can deteriorate.

The timing challenge is acute: if a biosimilar candidate takes too long to develop, the originator drug’s exclusivity window may close or a competitor may reach the market first, and the first biosimilar often captures the largest market share. Alvotech must balance speed with regulatory and scientific rigor.

The warrant angle and the SPAC path

Alvotech pursued a SPAC merger as a way to access public capital markets without a traditional IPO. This approach allowed the company to raise capital to fund development and commercialisation faster than a private funding round would enable. The warrants (ALVOW) are part of the SPAC’s capital structure and give holders leveraged exposure to whether Alvotech’s pipeline succeeds.

For warrant holders, the risks are compounded. The company must not only identify good biosimilar targets and develop them successfully, but also navigate manufacturing, regulatory, and commercial challenges at each stage. A biosimilar that fails a clinical trial, faces unexpected regulatory hurdles, or launches into a market where prices have collapsed can wipe out shareholder value entirely. A biosimilar that succeeds, by contrast, can be highly profitable. The warrant’s time decay means warrant holders cannot simply wait indefinitely for success—the clock ticks on the expiration date.

Researching Alvotech and biosimilar investing

Investors in ALVOW warrants should review Alvotech’s pipeline of biosimilar candidates, the stage of development for each (preclinical, Phase 1, Phase 2, Phase 3, regulatory submission, approved), the target biologic drugs and their current market size, and any partnerships or manufacturing agreements in place. The company’s quarterly and annual SEC filings disclose pipeline status, cash burn rate, and strategic announcements.

Understanding the competitive dynamics of each target drug and the regulatory path to approval in key markets (U.S., Europe, Japan) is also essential. A biosimilar candidate for a drug that faces multiple competitors will have worse economics than one for a less-crowded market. Warrant holders should track clinical trial results and regulatory submissions to gauge the probability of successful development and launch.